PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth while AVXL is at 4.03%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-26.14%
Negative operating income growth while AVXL is at 4.03%. Joel Greenblatt would press for urgent turnaround measures.
-26.43%
Negative net income growth while AVXL stands at 40.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-26.52%
Negative EPS growth while AVXL is at 42.73%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-26.52%
Negative diluted EPS growth while AVXL is at 42.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.09%
Share reduction more than 1.5x AVXL's 1.50%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.09%
Diluted share reduction more than 1.5x AVXL's 1.50%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while AVXL is at 25.98%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.72%
Negative FCF growth while AVXL is at 25.98%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Negative 10Y OCF/share CAGR while AVXL stands at 61.82%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
12.78%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
32.48%
3Y OCF/share CAGR at 75-90% of AVXL's 38.34%. Bill Ackman would press for improvements in margin or overhead to catch up.
-18544.23%
Negative 10Y net income/share CAGR while AVXL is at 81.48%. Joel Greenblatt sees a major red flag in long-term profit erosion.
7.55%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
44.34%
3Y net income/share CAGR 50-75% of AVXL's 71.62%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
1862.49%
10Y equity/share CAGR above 1.5x AVXL's 253.45%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
309.42%
5Y equity/share CAGR 1.25-1.5x AVXL's 210.99%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
-81.93%
Negative 3Y equity/share growth while AVXL is at 41.81%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Negative asset growth while AVXL invests at 3.47%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-33.19%
We have a declining book value while AVXL shows 3.38%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
26.95%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
24.63%
SG&A growth well above AVXL's 8.79%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.